In a recent study published in Nature Medicine,Wang,Shao,and colleagues successfully addressed two critical issues of lung cancer(LC)screening with low-dose computed tomography(LDCT)whose widespread implementation,des...In a recent study published in Nature Medicine,Wang,Shao,and colleagues successfully addressed two critical issues of lung cancer(LC)screening with low-dose computed tomography(LDCT)whose widespread implementation,despite its capacity to decrease LC mortality,remains challenging:(1)the difficulty in accurately distinguishing malignant nodules from the far more common benign nodules detected on LDCT,and(2)the insufficient coverage of LC screening in resource-limited areas.1 To perform nodule risk stratification,Wang et al.developed and validated a multi-step,multidimensional artificial intelligence(AI)-based system(Fig.1)and introduced a data-driven Chinese Lung Nodules Reporting and Data System(C-Lung-RADS).1 A Lung-RADS system was developed in the US to stratify lung nodules into categories of increasing risk of LC and to provide corresponding management recommendations.展开更多
基金funding from the European Union-NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3 Project PE_00000019“HEAL ITALIA”to Stefano Diciotti-CUP J33C22002920006.
文摘In a recent study published in Nature Medicine,Wang,Shao,and colleagues successfully addressed two critical issues of lung cancer(LC)screening with low-dose computed tomography(LDCT)whose widespread implementation,despite its capacity to decrease LC mortality,remains challenging:(1)the difficulty in accurately distinguishing malignant nodules from the far more common benign nodules detected on LDCT,and(2)the insufficient coverage of LC screening in resource-limited areas.1 To perform nodule risk stratification,Wang et al.developed and validated a multi-step,multidimensional artificial intelligence(AI)-based system(Fig.1)and introduced a data-driven Chinese Lung Nodules Reporting and Data System(C-Lung-RADS).1 A Lung-RADS system was developed in the US to stratify lung nodules into categories of increasing risk of LC and to provide corresponding management recommendations.
